Amid downturn, JPM’s Gaito reminds biotech of its risk-sharing roots 

As biopharma investors and executives continue to grapple with the now year-long downturn, J.P. Morgan’s Mike Gaito told The BioCentury Show that the sector has already begun to return to its bootstrapping roots by cutting burn rates, focusing on core programs and revisiting risk-sharing deals and partnerships.

The current market environment is familiar to Gaito, who is J.P. Morgan’s global head of healthcare investment banking and has been in the industry for 26 years...